{"id":347,"date":"2020-07-02T06:57:53","date_gmt":"2020-07-02T13:57:53","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=347"},"modified":"2020-10-23T07:00:13","modified_gmt":"2020-10-23T14:00:13","slug":"derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/","title":{"rendered":"Derm-Biome Pharmaceuticals, Inc. sammelt Vorfinanzierung und gr\u00fcndet ein neues Unternehmen mit Schwerpunkt auf chronischen Entz\u00fcndungskrankheiten"},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]<\/p>\n

\n
\n
\n
\n

VANCOUVER, British Columbia, 2. Juli 2020 (GLOBE NEWSWIRE) \u2013 Derm-Biome Pharmaceuticals, Inc, ein in Vancouver ans\u00e4ssiges pr\u00e4klinisches biopharmazeutisches Unternehmen mit Schwerpunkt auf Hautkrankheiten und gesundem Altern, freut sich bekannt zu geben, dass es $500.000 an Pre-Seed gesammelt hat Finanzierung, Gelder, die es ihm erm\u00f6glichen werden, seine Anti-Aging- (Hautverj\u00fcngung) und Neurodermitis-Topika bis zum ersten Quartal 2021 in die Klinik zu bringen.<\/p>\n

Dar\u00fcber hinaus wurde ein neues und unabh\u00e4ngiges Biotech-Unternehmen namens Pan-Biome Pharmaceuticals, Inc. ausgegliedert, das sich auf die Entwicklung von Arzneimitteln f\u00fcr chronisch entz\u00fcndliche Erkrankungen konzentrieren wird. Das neue Unternehmen wird mit kleinen Molek\u00fclen im Fr\u00fchstadium beginnen, die in pr\u00e4klinischen Studien eine starke entz\u00fcndungshemmende Wirkung gezeigt haben und die Produktion von Zytokinen hemmen, die bei vielen chronisch entz\u00fcndlichen Erkrankungen \u00fcberexprimiert werden. Die Verbindungen verf\u00fcgen au\u00dferdem \u00fcber eine antimikrobielle Aktivit\u00e4t, die m\u00f6glicherweise dazu beitr\u00e4gt, das Darmmikrobiom auszugleichen und zu diversifizieren.<\/p>\n

Chronische Entz\u00fcndungen spielen eine zentrale Rolle bei einigen der schwierigsten Krankheiten unserer Zeit, darunter rheumatoide Arthritis, Krebs, Herzerkrankungen, Diabetes, Asthma und Alzheimer. Eine ver\u00e4nderte Mikrobiota-Zusammensetzung im Darm wird mit entz\u00fcndlichen Erkrankungen wie entz\u00fcndlichen Darmerkrankungen, Fettleibigkeit, Lebererkrankungen, Parkinson-Krankheit und Darmkrebs in Verbindung gebracht. Chronische Entz\u00fcndungen schreiten langsam voran, sind jedoch die Ursache der meisten chronischen Krankheiten und stellen eine gro\u00dfe Bedrohung f\u00fcr die Gesundheit und Langlebigkeit des Einzelnen dar.<\/p>\n

Gordon Eberwein, CEO von Derm-Biome: \u201eWir freuen uns sehr \u00fcber die Aussichten f\u00fcr Pan-Biome aufgrund der weitreichenden entz\u00fcndungshemmenden und antibakteriellen Eigenschaften unserer Verbindungen.\u201c Wir freuen uns auch auf die Zusammenarbeit mit unseren neuen Investoren, die umfangreiche Finanzierungs- und M&A-Erfahrung im Life-Science-Bereich mitbringen.\u201c<\/p>\n

Pan-Biome wird noch in diesem Sommer mit Tests an pr\u00e4klinischen Modellen in verschiedenen Indikationen beginnen, einschlie\u00dflich der Verwendung eines neuen Verabreichungssystems, das gr\u00f6\u00dfere und gezieltere Medikamentenmengen erm\u00f6glichen wird. Antr\u00e4ge f\u00fcr klinische Studien werden voraussichtlich im ersten Halbjahr 2021 eingereicht.<\/p>\n

\u00dcber Derm-Biome Pharmaceuticals, Inc<\/strong><\/p>\n

Derm-Biome Pharmaceuticals, Inc. ist ein pr\u00e4klinisches biopharmazeutisches Unternehmen mit \u00fcber 40 nat\u00fcrlichen Derivaten, Salzen und Co-Kristallen, das sich der Verbesserung der Hautgesundheit und eines gesunden Alterns widmet. Unsere Verbindungen sind gut vertr\u00e4glich und weisen neuartige entz\u00fcndungshemmende, antimikrobielle, antioxidative und antitumorale Eigenschaften auf.<\/p>\n

Kontakt<\/strong>
\nInvestoren- und Kooperationsanfragen:
\nGordon Eberwein
\ngeberwein@derm-biome.com<\/u><\/a>
\nhttps:\/\/derm-biomepharmaceuticals.com\/<\/u><\/a>
\nhttps:\/\/pan-biomepharmaceuticals.com\/<\/u><\/a><\/p>\n

 <\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing, is pleased to announce that it has raised $500,000 in pre-seed funding, monies that will allow it to advance its anti-aging (skin […]<\/p>","protected":false},"author":2,"featured_media":348,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-347","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news"],"yoast_head":"\nDerm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing, is pleased to announce that it has raised $500,000 in pre-seed funding, monies that will allow it to advance its anti-aging (skin […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-02T13:57:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-23T14:00:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"539\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschrieben von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases\",\"datePublished\":\"2020-07-02T13:57:53+00:00\",\"dateModified\":\"2020-10-23T14:00:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\"},\"wordCount\":413,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\",\"name\":\"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg\",\"datePublished\":\"2020-07-02T13:57:53+00:00\",\"dateModified\":\"2020-10-23T14:00:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg\",\"width\":1000,\"height\":539},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/","og_locale":"de_DE","og_type":"article","og_title":"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases - Derm-Biome Pharmaceuticals Inc.","og_description":"[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing, is pleased to announce that it has raised $500,000 in pre-seed funding, monies that will allow it to advance its anti-aging (skin […]","og_url":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2020-07-02T13:57:53+00:00","article_modified_time":"2020-10-23T14:00:13+00:00","og_image":[{"width":1000,"height":539,"url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg","type":"image\/jpeg"}],"author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"Geschrieben von":"Derm-Biome Admin","Gesch\u00e4tzte Lesezeit":"2 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases","datePublished":"2020-07-02T13:57:53+00:00","dateModified":"2020-10-23T14:00:13+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/"},"wordCount":413,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg","articleSection":["Recent News"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/","url":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/","name":"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg","datePublished":"2020-07-02T13:57:53+00:00","dateModified":"2020-10-23T14:00:13+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#primaryimage","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/10\/Announcement-Photo-2020Oct.jpg","width":1000,"height":539},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-raises-pre-seed-funding-spins-out-new-company-focused-on-chronic-inflammatory-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases"}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/comments?post=347"}],"version-history":[{"count":1,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/347\/revisions"}],"predecessor-version":[{"id":350,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/347\/revisions\/350"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media\/348"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media?parent=347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/categories?post=347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/tags?post=347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}